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Galectin-1 Knockdown Increases Sensitivity
to Temozolomide in a B16F10 Mouse Metastatic
Melanoma Model
Ve´ronique Mathieu1, Marie Le Mercier1, Nancy De Neve2, Se´bastien Sauvage2, Thierry Gras2,
Isabelle Roland2, Florence Lefranc1,3 and Robert Kiss1
The rapid increase in the incidence of malignant melanomas has not been associated with improved
therapeutic options over the years. Indeed melanomas have proven resistant to apoptosis (type I programmed
cell death (PCD)) and consequently to most chemotherapy and immunotherapy. It is believed that this
resistance can be partly overcome by proautophagic drugs inducing type II (autophagy) PCD. Change at the
genomic, transcriptional, and post-translational level of G-proteins and protein kinases, including Ras, plays an
important role in the ability of melanomas to resist apoptosis. Ras transformation itself requires membrane
anchorage and the overexpression of galectin-1 increases membrane-associated Ras. In this study, it has been
found that decreasing galectin-1 expression in B16F10 mouse melanoma cells in vitro by means of an anti-
galectin-1 small interfering RNA approach does not modify their sensitivity to type I and type II PCD. However, it
does induce heat shock protein 70-mediated lysosomal membrane permeabilization, a process associated with
cathepsin B release into the cytosol, which in turn is believed to sensitize the cells to the proautophagic effects
of temozolomide when grafted in vivo. Furthermore, temozolomide when compared to the proapoptotic drug
cisplatin, significantly increased the survival times of mice in the B16F10 melanoma model.
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INTRODUCTION
Although melanomas account for only 4% of all dermatolo-
gical cancers, they are responsible for 80% of deaths from
skin cancer and only 14% of patients with metastatic
melanoma survive for 5 years (Miller and Mihm, 2006). The
rapid increase in the incidence of malignant melanomas has
not been associated with any improved therapeutic options
over the years (Atallah and Flaherty, 2005) and melanomas
have proved to be resistant to most chemotherapy and
immunotherapy (Hersey, 2006).
Despite a range of different biochemical targets, most agents
kill cancer cells by the induction of apoptosis, the type I
programmed cell death (PCD) (Hersey, 2006). This includes
cisplatin in melanoma cells (He et al., 2005; Del Bello et al.,
2006), yet melanomas are more or less resistant to apoptosis
(Ivanov et al., 2003; Hersey, 2006). Currently, the best response
rate achieved by chemotherapy or biochemotherapy for
melanoma is only 16%, although great hope is being placed in
the dimethyltriazinoimidazole carboxamide analog (DiTc),
temozolomide (Atallah and Flaherty, 2005; Tas et al., 2005).
Cell death is most commonly associated with apoptosis but it can
also occur through other mechanisms, including autophagy, that
is type II PCD. This dynamic process, which involves the
degradation and recycling of intracellular components in
response to cellular stress or starvation, can either promote cell
adaptation and survival or lead to cell death and thus could be of
potential therapeutic value (Kondo et al., 2005). Temozolomide
induces type II PCD (Kanzawa et al., 2004) as a consequence but
could lead to late apoptosis (Roos et al., 2007). It is currently
being evaluated in the treatment of glioblastomas (Lefranc et al.,
2005, 2006), which are also resistant to type I PCD.
It is known that cancer cells migrating through systemic
circulation need to survive in suspension and so need to resist
anoı¨kis PCD (Douma et al., 2004). Numerous publications
have also demonstrated a link between a highly migrating
metastatic phenotype and resistance to apoptosis in different
cancer types including melanoma (Glinsky and Glinsky,
1996; Lefranc et al., 2005; Decaestecker et al., 2007).
However, recent data indicate that compounds able to
reduce the levels of migration in migrating PCD-resistant
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cancer cells are also able to restore a certain level of
sensitivity to PCD and thus to cytotoxic agents (Lefranc et al.,
2005; Decaestecker et al., 2007). This was previously
validated experimentally in the case of human glioma
orthotopic xenografts, where decreasing the expression of
galectin-1 significantly decreased their migration level and in
turn increased the therapeutic benefit of temozolomide
(Camby et al., 2006). In vivo siRNA-induced decreases of
galectin-1 expression in experimental models of human
orthotopic glioblastoma xenografts contribute therapeutic
benefits. Am Assoc Cancer Res; AACR Annual Meeting,
abstract 2186).
Galectins are a phylogenetically conserved family of
lectins defined as sharing a consensus of sequences of about
130 amino acids related to the carbohydrate recognition
domain, responsible for b-galactoside binding (Danguy et al.,
2002; Liu and Rabinovich, 2005). Fifteen mammalian
galectins have been identified to date (Liu and Rabinovich,
2005). Galectin-1 modifies the migration level of human
cancer cells (Camby et al., 2006), especially in gliobla-
stomas (Camby et al., 2002; Stillman et al., 2005). In fact,
galectin-1 is expressed differentially by various normal and
pathological tissues and appears to be functionally multi-
valent, with a wide range of biological activities (Camby
et al., 2006). Galectin-1 expression or overexpression in
tumors or surrounding tissues must be considered as a sign
of malignant tumor progression that often relates to the long-
range dissemination of cancer cells (metastasis), to their
dissemination into the surrounding normal tissue, and to
tumor immune-escape (Liu and Rabinovich, 2005; Camby
et al., 2006) as galectin-1 kills activated T cells (Perillo et al.,
1995; Rubinstein et al., 2004; Stillman et al., 2006). Galectin-
1 is also suspected of displaying many different roles in
melanoma cell biology (Tinari et al., 2001; Rubinstein et al.,
2004), as is the case for other galectins (Kageshita et al.,
2002; Zubieta et al., 2006) but these roles remain largely
unexplored. The aim of this study is to investigate in vitro and
in vivo the role played by galectin-1 in the case of B16F10
mouse melanoma cell resistance to PCD. For this purpose,
we used a short interfering RNA (siRNA) approach to
decrease the level of galectin-1 expression in B16F10
cells and investigated the sensitivity of these cells to the
proautophagic drug temozolomide.
RESULTS
In vivo B16F10 mouse melanomas display a higher level
of sensitivity to the proautophagic drug temozolomide than
to cisplatin
Figure 1a illustrates the typical histopathology of a melanoma
that has developed in the lungs of mice 30 days after tail-vein
injection of B16F10 cells. These metastases showed a marked
galectin-1 staining (Figure 1c). It was not possible to compare
galectin-1 immunohistochemical expression in metastases
with that of primary tumors because (i) this B16F10 metastatic
model derives from direct intravenous (i.v.) injection of
melanoma cells into the tail vein and (ii) the subcutaneous
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Figure 1. B16F10 lung metastases model and its sensitivity to chemotherapeutics drugs. (a) Typical hematoxilin–eosin stained example of the histopathology
of a B16F10 melanoma (after B16F10 cell injection into the tail vein) which develops in the lungs of a tumor-bearing mouse after 30 days (bar¼500 mm).
(b) Negative control of the immunohistochemical staining of galectin-1 in the B16F10 lung metastasis from (a) (bar¼ 50 mm). (c) Morphological illustration
of its galectin-1 immunostaining (bar¼ 50 mm). (d) B6D2F1 mice had 2.5 105 B16F10 melanoma cells injected into their tail vein on day 0 and were
treated with temozolomide (40 mg/kg, blue line) or cisplatin (10 mg/kg, hatched red line; 20 mg/kg, red line). The anti-cancer drugs were administered i.v.
(tail vein) three times a week (on Mondays, Wednesdays, and Fridays) for four consecutive weeks, with drug treatment starting on day 7. The black line
represents the control group of untreated mice. There were 11 mice in each experimental group. (e) The experiment was identical to that detailed in (d), with
the black line representing the control group, the blue line 40 mg/kg temozolomide, the red line 5 mg/kg adriamycin, the orange line 10 mg/kg irinotecan,
and the green line 10 mg/kg taxol.
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graft of B16 melanoma cells does not lead to the formation of
metastases.
Using a drug schedule of three doses per week for 4
weeks, starting on day 7 post i.v. injection of B16F10 cells,
proautophagic drug temozolomide (40 mg/kg i.v.) was found
to significantly (Po0.01) increase survival times in this lung
metastatic model, whereas proapoptotic cisplatin at 10 and
20 mg/kg i.v. did not result in significant (P40.05) therapeu-
tic benefit (Figure 1d). The effects of temozolomide were
significantly greater (Po0.05) than those of cisplatin. The
doses were chosen on the basis of previous data obtained
with temozolomide in human orthotopic glioblastoma
xenografts (Branle et al., 2002) and with cisplatin in a
number of conventional mouse tumor models (Darro et al.,
2005). Higher doses of cisplatin are in fact toxic (Darro et al.,
2005).
In a second experiment, the activity of temozolomide,
again at 40 mg/kg i.v., in this metastatic B16F10 model was
confirmed (Figure 1e) and found to be similar to that of
proapoptotic drugs: adriamycin at 5 mg/kg i.v., irinotecan at
10 mg/kg i.v., and taxol at 10 mg/kg i.v. (Figure 1e). The doses
and schedules for taxol, irinotecan, and adriamycin were
chosen on the basis of data reported previously (Darro et al.,
2005).
In vitro proautophagic temozolomide displays weak cytotoxic
activity against human and mouse melanoma cells
In vitro taxol and SN-38, the active metabolite of irinotecan,
caused significant growth inhibition of human (C-32,
HT-144, and SKMEL-28) and mouse B16F10 melanoma cell
populations. Adriamycin and cisplatin both induced
markedly weaker inhibitory effects, whereas temozolomide
had no significant inhibitory effect at concentrations up to
10 mM (Table 1). Thus, the potent activity of temozo-
lomide observed in vivo in the case of experimental
melanoma models (Figure 1d and e) cannot be explained
by its weak cytotoxic activity in vitro (Table 1). Accordingly,
it was decided to decrease B16F10 cell galectin-1 expres-
sion in vitro and, once confirmed, to graft-transfected
cells in vivo to mice to reassess their sensitivity to
temozolomide.
Anti-galectin-1 siRNA reduces galectin-1 expression in B16F10
mouse melanoma cells
A specific anti-galectin-1 siRNA was found to maximally
decrease galectin-1 expression 5 days after the first transfec-
tion of B16F10 cells when compared to galectin-1 expression
in wild-type (untreated) and scrambled siRNA-treated
B16F10 cells (Figure 2a).
Furthermore, immunofluorescence analysis 7 days after
the transfection of B16F10 cells with this specific anti-
galectin-1 siRNA (Figure 2d and g) revealed that galectin-1
expression was still significantly decreased in 70–85% of the
treated cells, as compared to wild-type B16F10 cells (Figure
2b and e) or B16F10 cells transfected with the scrambled
siRNA (Figure 2c and f). Such sustained knockdown of galectin-
1 expression could be related, at least partly, to the fact that
the cells were transfected twice and/or to the possibly long
half-life galectin-1 itself. This successful procedure was
used for all subsequent experiments undertaken with
siRNA-transfected cells, using Western blotting to confirm
any decrease in galectin-1 expression as illustrated in
Figure 3g and h.
Decreasing the expression of galectin-1 in B16F10 melanoma
cells sensitizes cells to the anti-tumor effects of temozolomide
in vivo
Groups of B6D2F1 mice received i.v. injections in the tail
vein of wild-type B16F10 melanoma cells or cells transfected
in vitro 5 days before with scrambled siRNA or the anti-
galectin-1 siRNA. Western blotting confirmed the decrease in
galectin-1 expression in anti-galectin-1 siRNA-transfected
B16F10 cells compared to wild-type and scrambled siRNA-
transfected cells (Figure 3g and h).
Temozolomide administered i.v. at 40 mg/kg to the
defined schedule from 7 days post melanoma cell injection,
significantly increased the survival of the B16F10 melanoma-
bearing mice in the three experimental conditions under
investigation (implanted with (i) wild-type B16F10 cells
(P¼0.01), (ii) B16F10 cells transfected with the scrambled
siRNA (P¼0.002), or (iii) B16F10 cells transfected with the
anti-galectin-1 siRNA (P¼ 0.001)) (Figure 3a). However, the
most marked therapeutic effect of temozolomide occurred in
Table 1. Determination of the IC50 values (lM) of cytotoxic drugs on the overall growth levels of human
(C-32, HT-144, and SKMEL-28) and murine (B16F10) melanoma cell lines.
IC50 Values (lM)
1 against melanoma cell lines
Drugs C-32 HT-144 SKMEL-28 B16F10
Taxol 0.002+0.001 0.003+0.001 0.042+0.002 0.002+0.001
SN-38 0.001+0.001 0.042+0.002 0.044+0.002 0.082+0.002
Adriamycin 1.04+0.02 2.12+0.02 4.03+0.04 0.22+0.04
Cisplatin 4.02+0.03 10.03+0.03 410 10.01+0.03
Temozolomide 410 410 410 410
1The IC50 value (mM) is the concentration of the drug that decreases the overall growth of a tumor cell population by 50% three days after the culture of the
tumor cells in the presence of the drug. Overall growth determination was carried out by means of the 3-[4,5-dimethylthiazol-2yl]-dephenyltetrazolium
bromide colorimetric assay. The data are given as mean+SEM values.
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mice grafted with melanoma cells transfected with the anti-
galectin-1 siRNA (Figure 3a), which was significantly
(Po0.01) better than that obtained with temozolomide in
mice grafted with wild-type or scrambled siRNA-transfected
cells.
It was also evident that the average weight of lungs excised
from animals grafted with anti-galectin-1 siRNA-transfected
B16F10 cells and subsequently treated with temozolomide
was appreciably lower than that of other treatment groups
(Figure 3b). These data suggest that the sensitization to
temozolomide on galectin-1 reduction, at least partly occurs
through a delay in the development of B16F10 lung
metastases.
Furthermore, histopathological analysis revealed that
B16F10 lung metastases obtained from mice grafted with
anti-galectin-1 siRNA-transfected cells (Figure 3c) showed
significantly (Po0.01) larger necrotic areas (Figure 3d) than
those obtained with scrambled siRNA-transfected cells
(Figure 3e). These necrotic areas in B16F10 lung metastases
correspond to the pink areas in Figure 3c, which are further
magnified in Figure 3f.
This marked necrotic process was considered to relate
partly to a modification in angiogenesis, a fact already
observed in glioma (Lefranc et al., manuscript submitted for
publication). Accordingly, the levels of angiogenesis in lung
tumors obtained in the above experiment were quantified
and revealed a significant decrease in the surface area
occupied by blood vessels in those tumors obtained following
injection of galectin-1-depleted cells compared to tumors
obtained after injection of scrambled siRNA-transfected cells
(Figure 4a and b).
The sensitization of galectin-1-depleted B16F10 melanoma cells
to the anti-tumor effects of temozolomide is not related to
galectin-1 depletion-induced decrease in B16F10 cell motility
As galectin-1 is known to markedly modify the level of
migration of certain cancer cells, that is glioma cells (Camby
et al., 2002) and this can in turn significantly increase their
sensitivity to cytotoxic drugs (Lefranc et al., 2005; Decaes-
tecker et al., 2007), it was decided to investigate whether
galectin-1 depletion sensitizes B16F10 melanoma cells in
vitro to the cytotoxic effects of temozolomide. Using the
scratch-wound assay which permits both growth and migra-
tion features of a tumor cell population to be investigated
(Mathieu et al., 2005b; Decaestecker et al., 2007), it was
found that it tookB24 hours for wild-type B16F10 melanoma
cells to recolonize 20% of the ‘‘mechanical’’ wound inflicted
on confluent B16F10 monolayers (Figure 5b vs a). Temozo-
lomide (10 mM) did not significantly (P40.05) modify wound
healing in wild-type or scrambled siRNA-transfected B16F10
monolayers during the 24-hour observation period (Figure
5c). In contrast, reduction of galectin-1 in B16F10 melanoma
cells weakly but nevertheless significantly (Po0.05) inhibited
the wound-healing process per se (Figure 5c) and signifi-
cantly (Po0.001) sensitized these anti-galectin-1 siRNA-
transfected-B16F10 cells to temozolomide (Figure 5c).
The quantitative determination of the levels of migration of
individual B16F10 cells was undertaken using computer-
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Figure 2. Transient galectin-1 depletion in B16F10 cells in vitro. (a) Western blotting analyses showing that anti-galectin-1 siRNA decreased galectin-1
expression for at least 5 days as compared to the levels of galectin-1 expression in wild-type (wt) and scrambled (scr) siRNA-transfected B16F10 cells.
(b) Immunofluorescence analyses also showed that the level of expression of galectin-1 was significantly reduced in 70–85% of the B16F10 melanoma cells
treated with the anti-galectin-1 siRNA 7 days before (g with corresponding bright field microscopy given in d) as compared to (b and e) the wild-type and
(c and f) scrambled siRNA-transfected B16F10 cells (bar¼200 mm).
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assisted phase-contrast microscopy (Debeir et al., 2005).
Figure 5d typically illustrates an initial B16F10 cell popula-
tion submitted for quantitative determination of cell migra-
tion. Figure 5e illustrates the same B16F10 cell population
24 hours later, while Figure 5f illustrates the trajectories
traveled by each individual B16F10 cell during the 24-hour
observation period. The analyses of the MRDO variable
(maximal relative distance to the origin converted in mm/
hour) based on these trajectories (Figure 5g) clearly indicate
that the reduction of galectin-1 in B16F10 cells did not
significantly modify their migration level. Thus, as revealed
by the scratch-wound assay (Figure 5c), the galectin-1
reduction-induced sensitization of B16F10 melanoma cells
to temozolomide is not related to galectin-1-induced
modifications to individual B16F10 melanoma cell migration
(Figure 5g). As the same cells used for the generation of data
reported in Figure 3 were used for these experiments, the
Western blotting confirmation of transfection illustrated in
Figure 3g and h also served as a control for the experiments
detailed here.
Galectin-1 depletion of B16F10 melanoma cells does not
sensitize cells to either apoptosis or autophagy
TUNEL staining analyzed by flow cytometry showed that the
depletion of galectin-1 in the B16F10 cells did not induce any
marked apoptotic process (Figure 6a). As expected from the
data reported by Kanzawa et al. (2004), temozolomide (50 mM
for 72 hours) did not induce apoptosis in wild-type B16F10
cells (Figure 6a). In addition, the depletion of galectin-1
expression in B16F10 cells also did not lead to any
temozolomide-induced proapoptotic effects (Figure 6a).
These data were further confirmed by the poly (ADP-ribose)
polymerase cleavage assay (Mathieu et al., 2005b; Mijatovic
et al., 2006), which revealed the presence of intact poly
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Figure 3. Galectin-1 depletion: effects on the B16F10 in vivo model and
its response to temozolomide. (a) The influence of 40 mg/kg temozolomide
(the hatched colored lines) on the survival of mice injected i.v. (tail vein) on
day 0 with either 2.5105 wild-type (wt, black lines) or scrambled siRNA-
(scr, green lines) and anti-galectin-1 siRNA (si, red lines)-transfected B16F10
melanoma cells. The experimental protocol is identical to the one detailed in
Figure 1d and its legend. (b) After killing, the lungs from each mouse in the
experiment detailed in (a) were weighed and mean weights7SEM per
treatment group determined. The lungs were then fixed for histological
analyses. (c and e): Typical hematoxilin–eosin-stained example of the
histopathology of lung metastases 30 days after mice have been injected with
(c) anti-galectin-1 siRNA-transfected B16F10 cells (e) or with scrambled
siRNA-transfected B16F10 cells (bar¼ 200mm). (d) Quantitative
determination of the mean percentage of necrotic area7SEM of B16F10 lung
metastases from mice in (a) that have been injected i.v. with scrambled
siRNA- or anti-galectin-1 siRNA-transfected B16F10 melanoma cells.
For each experimental condition, a minimum of 35 fields was analyzed.
(f) Higher magnification (hematoxilin–eosin staining) of a necrotic area
observed in a B16F10 lung metastasis (bar¼ 50mm). (g and h) Additional
control: using Western blotting, confirmation of galectin-1 depletion in
anti-galectin-1 siRNA-transfected B16F10 cells used in experiments
detailed in this figure.
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Figure 4. Galectin-1 depletion has anti-angiogenic effects. (a) Illustration of
the typical field of a melanoma lung metastasis obtained after the graft of
scrambled siRNA-transfected cells (bar¼ 50 mm). It contains two blood
vessels. To quantify the angiogenesis, we used a grid to measure the area
covered by blood vessels as illustrated in (a). Quantitative angiogenesis data
for lung metastases derived from scrambled (scr) siRNA-transfected or anti-
galectin-1 siRNA (si)-transfected B16F10 cells expressed as a percentage of
the analyzed surface are given in (b) as mean7SEM values. As 10 fields per
tumor were analyzed, between 60 and 90 measurements were undertaken for
each experimental condition.
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(ADP-ribose) polymerase (molecular mass, 116 kDa) in wild-
type, scrambled-siRNA-, and anti-galectin-1 siRNA-trans-
fected cells (Figure 6a inset). Fragments representative of
apoptosis (83–89 kDa) were nevertheless obtained in adria-
mycin-treated MCF-7 cells (positive control), whereas necro-
sis (50–60 kDa) was absent (Figure 6a inset). Furthermore, the
depletion of galectin-1 in B16F10 melanoma cells did not
seem to interfere with the acutely transforming retrovirus
(Akt) survival-signaling pathway (Toker and Yoeli-Lerner,
2006). Indeed, no changes in the expression of Akt or in its
activation in terms of the levels of Ser473p- and Thr308p-
phosphorylation were observed (Figure 6b).
Acridine orange staining revealed that temozolomide
provoked a marked increase in red fluorescence, which
reflects for the most part the acidic compartments of the cell,
in wild-type, scrambled siRNA-, and anti-galectin-1 siRNA-
transfected B16F10 cells (Figure 6c). Such acidic vesicular
organelles may be related to autophagic vacuoles in the cell
(Kondo et al., 2005). Indeed, the proautophagic activity of
temozolomide was confirmed by increased expression of
LC3-II and/or beclin-1 (a specific marker of autophagy
(Kondo et al., 2005; Pattingre and Levine, 2006; Figure 6d))
in wild-type and scrambled siRNA-transfected cells (Figure
6d). LC3 is the microtubule-associated protein light-chain 3,
a mammalian homolog of Apg8p/aut7p essential for amino-
acid starvation-induced autophagy in yeast (Kanzawa et al.,
2004; Kondo et al., 2005). In contrast, the depletion of
galectin-1 in B16F10 melanoma cells did not appear to
provoke any enhanced proautophagic effects, as the levels of
expression of beclin-1, LC3-I, and LC3-II (Figure 6d) were
similar in the wild-type, scrambled siRNA-transfected, and
anti-galectin-1 siRNA-transfected B16F10 melanoma cells.
The same conclusion can be drawn with respect to the effect
of temozolomide on galectin-1-depleted cells (Figure 6c and d).
Galectin-1 depletion in B16F10 cells is associated with a Hsp70
decrease-associated lysosomal membrane permeabilization
Although the red fluorescence observed after acridine orange
staining could relate to acidic (and so in part autophagic)
compartments, green fluorescence has been shown to
increase in the case of lysosomal membrane permeabilization
(LMP; Nylandsted et al., 2004). Such a possibility was
strongly suggested by the data illustrated in Figure 7a.
Indeed, lysosomes can function as death signal integrators
that mediate caspase- and/or apoptosis-inducing factor-
independent PCD (Fehrenbacher and Ja¨a¨ttela¨, 2005). The
modifications to the acridine orange staining shown in Figure
7a can be indicative of a leakage of acridine orange from the
acidic compartment into the cytosol (Nylandsted et al.,
2004). This hypothesis was confirmed by the use of the
acidophilic fluorescent Lysotrackers dye, which is more
specific than acridine orange. The marked and perinuclear
staining obtained in the wild-type (data not shown) and
scrambled-siRNA-transfected cells (Figure 7b and c) was
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Figure 5. Galectin-1 depletion effects on cell migration. Scratch-wound assay on a B16F10 cell population grown until confluence and on which a
‘‘mechanical’’ wound had been made (a) at time 0. (b) Twenty-four hours later, the B16F10 cells had recolonized about 20% of the wound (bar¼ 200mm).
(c) Quantitative determination (computer-assisted videomicroscopy) of the ability of wt, scrambled RNA- and anti-galectin-1 siRNA-transfected B16F10
melanoma cells to recolonize the wound (illustrated in (a)) in the absence (open bars in (c)) or in the presence of 10 mM temozolomide (black bars in (c)).
The data are given as the means of 12 measurements7SEM values. The experiments were performed in triplicate. (d–f) Quantitative determination by means
of computer-assisted phase-contrast microscopy of the migration levels of individual B16F10 cells at (d) time 0 and (e) after 24 hours, with (f) illustrating the
trajectories traveled by the individual B16F10 cells over this 24-hour period of observation (bar¼200 mm). (g) The largest linear distance traveled by each
individual B16F10 cell during this 24-hour period of observation was computed and normalized as the distance traveled in mm/hour (maximal relative
distance to the origin). The rest of the legend for (g) is identical to (d–f). As the experiment was conducted in quadruplicate, a minimum of 121 and a maximum
of 238 cells were analyzed for each experimental condition.
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nearly completely abolished in the anti-galectin-1 siRNA-
transfected cells (Figure 7d and e), indicating a decrease of
the acidic content of lysosomes, which could in turn be
related to LMP. Additional evidence of a galectin-1 deple-
tion-mediated LMP process in B16F10 melanoma cells was
provided by the immunofluorescence analyses of cathepsin B
staining (Figure 7h, i, and j). Cathepsin B seems to be
contained in the lysosomes of untreated cells (Figure 7h) as its
staining was concentrated in the perinuclear region, and was
punctuated and similar to that of lysosomal associated
membrane protein 2(a specific marker of the lysosomal
membrane; Figure 7f (Eskelinen, 2006)). In contrast, cathep-
sin B staining was significantly decreased and quite diffused
in anti-galectin-1 siRNA-transfected B16F10 cells (Figure 7i
and j). This could indicate galectin-1 depletion-induced
leakage of lysosomes, as the staining patterns of cathepsin B
(Figure 7i) and the lysosomal marker lysosomal associated
membrane protein 2 (the latter remaining unchanged; Figure
7g) no longer corresponded.
One of the anti-cell death mechanisms active in melano-
ma cells involves the overexpression of heat shock protein 70
(Hsp70; Schmitt et al., 2006), which fulfils its prosurvival
function by inhibiting LMP (Nylandsted et al., 2004). Hsp70
is under the transcriptional control of the activator nuclear
factor of activated T cell (NFAT)5/TonEBP (Na et al., 2003)
and galectin-1 is known to be able to modify the activation of
NFAT members (Walzel et al., 2002). Figure 7o shows that
the decrease in galectin-1 expression in B16F10 cells induced
by anti-galectin-1 siRNA was accompanied by a significant
(Po0.001) decrease in Hsp70 expression, the morphological
expression of which is illustrated in Figure 7l and n.
DISCUSSION
The most aggressive melanomas are resistant to strategies
targeting any one signaling pathway, therefore multiple
signaling pathways may need to be targeted for maximum
therapeutic effectiveness (Smalley et al., 2006). Of key
importance in melanoma resistance to apoptosis are changes
at genomic, transcriptional, and post-translational levels in
G-proteins and protein kinases (Ras, B-Raf) and their
transcription factor effectors which affect tumor necrosis
factor, Fas, and tumor necrosis factor-related apoptosis-
inducing ligand receptors (Ivanov et al., 2003; Miller and
Mihm, 2006; Smalley et al., 2006). Ras genes promote
malignant transformation (Paz et al., 2001) and are frequently
mutated in human tumors and in melanomas in particular
(Miller and Mihm, 2006). Ras transformation requires
membrane anchorage, which is promoted by the over-
expression of galectin-1 (Paz et al., 2001). This later increases
membrane-associated Ras, Ras–guanosine triphosphate, and
active extracellular signal-related kinase and results in cell
transformation which is blocked by dominant-negative Ras
(Paz et al., 2001). Galectin-1 could thus be involved in the
aggressive behavior of melanoma cells if its partnership with
Ras is taken into account. We have therefore investigated
melanoma cell sensitivity to the proautophagic effects of
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Figure 6. Galectin-1 depletion-induced sensitivity to type I and II PCD. (a) Flow cytometry analyses of TUNEL staining (a) in the case of wild-type (wt),
scrambled siRNA- (scr), and anti-galectin-1-siRNA (si)-transfected B16F10 melanoma cells treated for 72 hours with 50 mM temozolomide (black bars)
or left untreated (open bars). Inset represents the poly (ADP-ribose) polymerase cleavage control analysis for the absence of apoptosis in a. The positive
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analyses of the red fluorescence obtained by acridine orange staining in wild-type, scrambled siRNA-, and anti-galectin-1-siRNA-transfected B16F10 melanoma
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scrambled siRNA-, and anti-galectin-1-siRNA-transfected B16F10 melanoma cells either treated for 72 hours with 50 mM temozolomide or left untreated.
Data are presented as meanþ SEM values of three experiments.
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temozolomide in B16F10 melanoma cells expressing high
versus reduced levels of galectin-1.
With respect to PCD, galectin-1 induces the inhibition of
cell growth and cell-cycle arrest and promotes the apoptosis
of activated but not of resting immune cells (Liu and
Rabinovich, 2005; Camby et al., 2006). The signal transduc-
tion events that lead to cell death induced by galectin-1 in
activated T cells involve several intracellular mediators
including the induction of specific transcription factors (i.e.
NFAT and activator protein-1; Camby et al., 2006). Decreas-
ing galectin-1 expression in B16F10 melanoma cells does not
induce apoptosis or autophagy in these cells. In contrast, this
decrease in galectin-1 expression in these melanoma cells
appears to induce LMP, which in turn synergizes the effects of
temozolomide. As recently reviewed by Kroemer and Ja¨a¨ttela¨
(2005), lysosomal alterations are common in cancer cells.
Indeed, increased expression and altered trafficking of
lysosomal enzymes play a key role in tissue invasion,
angiogenesis, and sensitization to the lysosomal death
pathway, whereas the lysosomal Hsp70 locally prevents
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Figure 7. Decreasing galectin-1 expression induces LMP. (a) Flow cytometry analyses of the green fluorescence obtained by acridine orange staining in
wild-type (wt), scrambled siRNA- (scr), and anti-galectin-1-siRNA (si)-transfected B16F10 melanoma cells. Data are presented as meanþ SEM values of three
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protein 2 protein in red and cathepsin B in green in (f and h, respectively) scrambled siRNA- and (g and i, respectively) anti-galectin-1 siRNA-transfected B16F10
melanoma cells (bar¼ 200mm). (j) Shows the quantification of the modified expression pattern of cathepsin B expression illustrated in (g–i). The data are
presented as the means of the fluorescence levels of a minimum of 70 and a maximum of 95 cells7SEM values. (k–n) Immunofluorescent staining for galectin-1
(red fluorescence) and Hsp70 (green fluorescence) in (k and l, respectively) scrambled siRNA- (m and n) and anti-galectin-1 siRNA-transfected B16F10
melanoma cells (bar¼ 200mm). (o) Quantitative determination of the staining for galectin-1 (black bars) and Hsp70 (open bars) in scrambled siRNA- and
anti-galectin-1 siRNA-transfected B16F10 melanoma cells. The data are presented as the mean of the fluorescence levels of a minimum of 48 and a maximum
of 57 cells7SEM values. The experiments were undertaken twice in triplicate. The quantitative data were obtained by the analysis of one set of triplicates.
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LMP (Kroemer and Ja¨a¨ttela¨, 2005). Indeed, the membrane
localization of Hsp70, found in 80% of human cancer
biopsies provides tumor lysosomes with increased resistance
to LMP (Kroemer and Ja¨a¨ttela¨, 2005). As this subcellular
localization of Hsp70 seems to be cancer-specific, targeting
Hsp70 might have selective therapeutic effects (Kroemer and
Ja¨a¨ttela¨, 2005). Decoy interactors such as the apoptosis-
inducing factor-derived Hsp70 decoy (ADD70) has already
been shown to sensitize B16F10 melanoma cells to the
proapoptotic effects of cisplatin (Schmitt et al., 2003).
Cisplatin was not used in this study to challenge PCD
resistance of B16F10 cells depleted in galectin-1 because
temozolomide offered greater therapeutic benefits than
cisplatin (Figure 1). The present data indicate that galectin-1
depletion-induced LMP in B16F10 melanoma cells occurs
along with a decrease in Hsp70 expression. In fact, galectin-1
could, at least partly, control Hsp70 expression because it
activates certain members of the NFAT family (Walzel et al.,
2002) and Hsp70 expression is under the control of NFAT
elements (Na et al., 2003).
These data suggest that targeting autophagy in melanomas
could, at least partly, overcome their resistance to apoptosis
(Paz et al., 2001; Ivanov et al., 2003; Miller and Mihm,
2006). Moreover, the observed synergy between the galectin-
1 depletion-induced LMP and the proautophagic effects of
temozolomide can be related to the interconnection between
these two processes, with lysosomes controlling cell death at
several levels (Kroemer and Ja¨a¨ttela¨, 2005). Under physiolo-
gical conditions, lysosomal hydrolases participate in orga-
nelle and macromolecule turnover through autophagy, acting
within the tight compartment of the lysosome (in the case of
microautophagy or chaperone-mediated autophagy) or the
autophagolysosome (the organelle created by the fusion of a
lysosome with an autophagic vacuole (autophagosome)),
which is a characteristic of macroautophagy (Kondo et al.,
2005; Kroemer and Ja¨a¨ttela¨, 2005). LMP may occur in
response to endogeneous or exogeneous stress and lead to
the release of catabolic hydrolases that can mediate caspase-
dependent apoptosis, caspase-independent apoptosis-like
cell death, or even necrosis following high levels of LMP
(Kroemer and Ja¨a¨ttela¨, 2005). The in vitro data from this study
show that decreasing the levels of expression of galectin-1 in
B16F10 melanoma cells induces marked LMP processes with
a significant release of cathepsin B into the cytosol of these
cells (Figure 7h–i) and marked necrosis in vivo (Figure 3c–f).
This necrosis could also be partly related to galectin-1
depletion-induced impairment of neo-angiogenesis demon-
strated in vivo in this study (Figure 4). In fact, the same
phenomenon has been observed on decreasing galectin-1
expression in human Hs683 glioblastoma orthotopic xeno-
grafts in the brains of immunodeficient mice (Lefranc et al.,
manuscript submitted for publication). In this glioma model,
neither apoptotic nor autophagic features were observed in
vitro. In contrast, galectin-1 depletion sensitized glioma cells
to temozolomide in vitro and in vivo by modulating the
expression of several genes involved in the response to
endoplasmic reticulum stress (Lefranc et al., manuscript
submitted for publication). Among these genes, HYOU1/
ORP150 has been shown to modulate angiogenesis via the
processing of vascular endothelial growth factor (Ozawa
et al., 2001). Reduced galectin-1 expression in Hs683
glioblastoma cells also leads to sustained decreases in
vascular endothelial growth factor expression, with severe
in vivo impairment of angiogenesis in Hs683 orthotopic
xenografts (Lefranc et al., manuscript submitted for publica-
tion). Whether ORP150 is also involved in the impairment of
angiogenesis observed in melanoma metastases remains to be
determined. It should also be emphasized that it has recently
been demonstrated that galectin-1 is proangiogenic (Thijssen
et al., 2006).
In conclusion, decreasing the expression of galectin-1 in
B16F10 murine melanoma cells induces a Hsp70-mediated
LMP process with cathepsin B released into the cytosol, a
process which in turn sensitizes B16F10 melanoma cells to
the proautophagic effects of temozolomide. The novel
aspects of galectin-1 function in the LMP process highlighted
in this study may be amenable to therapeutic manipulation
through compounds which suppress galectin-1 activity
(Ingrassia et al., 2006).
MATERIALS AND METHODS
Cell cultures
The B16F10 mouse melanoma cell line (ATCC code CRL-6475) was
obtained from the ATCC collection (Manassas, VA), as was also the
case for the human C-32 (ATCC: CRL-1585), HT-144 (ATCC: HTB-
63), and SKMEL-28 (ATCC: HTB-72) melanoma cell lines. Trypsi-
n–EDTA, fetal bovine serum, the cell culture media, and their
supplements were obtained from GibcoBRL (Invitrogen SA, Merel-
beke, Belgium). The fetal bovine serum was heat-inactivated for
1 hour at 561C. The melanoma cells were incubated at 371C in
sealed (air-tight) plastic Falcon dishes (Nunc, VWR, Leuven,
Belgium) in a 5% CO2 atmosphere.
Compounds
Temozolomide was purchased from Schering Plough (Brussels,
Belgium), adriamycin and irinotecan from Pfizer-Pharmacia (Puurs,
Belgium), taxol (Paclitaxel) from SA Bristol-Myers Squibb (Brussels,
Belgium), SN-38 (7-ethyl-10-hydroxycamptothecin) from Aventis
(Brussels, Belgium), and cisplatin from Sigma-Aldrich (Bornem,
Belgium).
siRNA directed against galectin-1 expression in B16F10
melanoma cells
Several siRNA nucleotides targeting murine galectin-1 and designed
by Eurogentec (Seraing, Belgium) were evaluated and one: sense: 50-
accugugccuacacuucaadTdT-30, antisense: 50-uugaaguguaggcacag
gudTdT-30, displayed in the case of B16F10 mouse melanoma cells
transfected twice (on day 0 and 1), a maximum galectin-1 knock-
down activity 5 days after the first transfection with anti-galectin-1
siRNA (as compared to control). We used the following correspond-
ing scrambled siRNA as a control: sense: 50-ggaaaucccccaacagu
gadTdT-30, antisense: 50-ucacuguugggggauuuccTdT-30.
The antisense and sense strands of the anti-galectin-1 and
scrambled siRNAs were annealed by the manufacturer in 50 mM
Tris pH 7.5–8.0, 100 mM NaCl in diethyl pyrocarbonate -treated
water. Calcium phosphate-mediated transfections were performed
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with the Promega Profection Mammalian Transfection Systems
(Leiden, The Netherlands) according to the manufacturer’s instruc-
tions. The final concentration of the siRNAs applied overnight to the
cells for the transfections was 20 nM.
B16F10 melanoma cell injection into the tail veins of B6D2F1
mice, leading to the formation of lung metastases
B16F10 pulmonary melanoma metastases were obtained in B6D2F1
female mice (17–19 g; Iffa Credo, Charles Rivers, Arbresle, France)
by the i.v. injection of 2.5 105 B16F10 cells into the tail vein, as
recently described by Cheng et al. (2005). All the mice in any one
experiment were grafted with B16F10 tumor cells on the same day.
Each experimental group was composed of a minimum of 11 and a
maximum of 15 (for the experiments with transfected cells) animals.
The experimental protocols are detailed in the Results sections and
in the legends to the figures.
All the in vivo experiments described in this study were
performed on the basis of authorization no. LA1230509 of the
Animal Ethics Committee of the Federal Department of Health,
Nutritional Safety, and the Environment (Belgium).
Histology
Each B16F10 melanoma-bearing mouse was killed (in a CO2
atmosphere) when it had lost 20% of its weight compared to that
determined at the time of the tumor graft. The lungs were removed,
fixed in buffered formalin, and these tissues were then embedded in
paraffin for conventional histopathological (hematoxilin–eosin stain-
ing) or immunohistochemical analyses of the galectin-1 expression
(Preprotech; TebuBio, Boechout, Belgium) with respect to the
procedure described by Mathieu et al. (2005a).
The percentages of necrotic areas in B16F10 lung melanomas
obtained in vivo after the injection of in vitro scrambled siRNA- and
anti-galectin-1 siRNA-transfected B16F10 cells were determined by
counting the areas of necrotic tissue in a 10 10 grid field (G 100).
The grid was included in the lens of the microscope. The same
procedure was used for the quantification of blood vessels (G 400)
(Mathieu et al., 2005b).
The MTT colorimetric assay for the in vitro determination of
cell population growth
Cell proliferation was assessed using the colorimetric 3-[4,5-
dimethylthiazol-2yl]-dephenyltetrazolium bromide (MTT) (Sigma,
Bornem, Belgium) assay, as described previously (Mathieu et al.,
2005b; Mijatovic et al., 2006). The cells were incubated for 72 hours
in the presence or absence of the drugs indicated above. The drug
concentrations used ranged between 109 and 105 M, with semi-log
concentration increases. The experiments were carried out in
sextuplicate.
The in vitro scratch-wound assay
As previously indicated, scrambled siRNA or anti-galectin-1 siRNA
were transfected twice into B16F10 cells on day 0 and 1. Wild-type,
scrambled, and anti-galectin-1 siRNA-treated B16F10 melanoma
cells were grown to confluence in six-well dishes until day 5.
Scratches were then made by creating a denuded linear region by
means of a pipette tip, as detailed previously (Mathieu et al., 2005b).
After the scratch, wild-type, scramble-treated, and anti-galectin-1
siRNA-treated B16F10 cells were washed twice with phosphate-
buffered saline before their incubation with temozolomide at 10 mM.
Four fields per well were photographed (Mathieu et al., 2005b).
Software developed in our laboratory was used to quantify the area
repopulated by the cells 24 hours after the scratch (Mathieu et al.,
2005b).
Computer-assisted phase-contrast microscope analysis for the
in vitro quantitative determination of the migration of
individual B16F10 cells
As previously, the scrambled siRNA or anti-galectin-1 siRNA were
transfected twice into B16F10 cells on day 0 and 1. The cell
migration experiments were then carried out on day 5. The anti-
galectin-1 siRNA-induced depletion of galectin-1 in the case of
B16F10 cell migration was characterized in vitro by the use of a
device described elsewhere (Debeir et al., 2005). The greatest linear
distance migrated by each B16F10 cell was calculated on the basis
of the trajectories covered by the cells. This distance, normalized by
the observation time for each cell analyzed, is the maximum relative
distance from the point of origin, that is the MRDO quantitative
variable, which in fact corresponds to the average linear distance
traveled by the course of a cell during a single hour (expressed in
mm/h) (Debeir et al., 2005). All the experiments were performed over
24 hours, with one image recorded every 4 minutes. As the analyses
were conducted in quadruplicate, a minimum of 121 and a
maximum of 238 cells were analyzed for each experimental
condition.
Flow cytometry analyses
TUNEL staining. Flow cytometry analyses of apoptotic versus
nonapoptotic-related cell death were carried out by means of the
TUNEL technique using an experimental protocol detailed else-
where by Maecker et al. (2000). Briefly, both the B16F10 control
cells and the scrambled siRNA- and siRNA anti-galectin-1-trans-
fected cells were either treated for 72 hours with temozolomide at a
concentration of 50mM or were incubated with the solvent alone.
Apoptosis was then assessed by the flow cytometry-based TUNEL
assay. Both nonadherent and adherent cells were harvested, pooled,
and fixed with 1% paraformaldehyde (1 hour) followed by 70%
ethanol (overnight). The next day, the cells were processed using the
APO-BRDU kit (Sigma-Aldrich) according to the manufacturer’s
instructions. Immediately after the staining reaction, analysis was
performed on an Epics XL MCL flow cytometer (Beckman Coulter,
Analis, Suarle´e, Belgium) equipped with a 488-nm argon laser.
Apoptosis was quantified by following the increase in FITC–deoxy-
uridine triphosphate labeling in temozolomide-treated cells as
compared to the control cells (solvent alone).
Acridine orange staining. Acidic vesicular organelles were
stained with acridine orange purchased from Polysciences (War-
rington, PA). In acridine orange-stained cells, the cytoplasm and
nucleus fluoresce green, whereas acidic compartments fluoresce red
(Kanzawa et al., 2004; Mijatovic et al., 2006). The intensity of the
red fluorescence is proportional to the degree of acidity and the
volume of acidic vesicular organelles, including autophagic
vacuoles (Mijatovic et al., 2006). By contrast, LMP induces an
increase in the cytoplasmic green fluorescence (Nylandsted et al.,
2004). The technical staining protocol was as follows: B16F10 cells
were stained with acridine orange for 15 minutes and removed from
2408 Journal of Investigative Dermatology (2007), Volume 127
V Mathieu et al.
Galectin-1 and Cell Death in Melanomas
the plate with trypsinization. The cells were then analyzed by flow
cytometry using an Epics XL MCL flow cytometer (Beckman Coulter)
(Kanzawa et al., 2004).
Protein expression level and activity
Western blotting analyses were carried out as described previously
(Mathieu et al., 2005b; Mijatovic et al., 2006). Cell extracts were
prepared by the lysis of subconfluent B16F10 cells in a boiling lysis
buffer (10 mM Tris pH 7.4, 1 mM Na3O4 V, 1% SDS, pH 7.4).
Between 20 and 30 mg of protein (evaluated by the bicinchoninic
acid protein assay; Pierce, Perbio Science, Erembodegem, Belgium)
were loaded onto a denaturating polyacrylamide gel (10%) and
blotted onto a polyscreen PDF membrane (NEN Life Science
Products, Boston, MA). The antibody (dilution 1/750) that was used
to characterize the levels of expression of the proautophagic marker
LC3 was kindly provided by Dr Yasuko Kondo (Department of
Neurosurgery, The University of Texas MD Anderson Cancer Center,
Houston, TX) and is described in Kanzawa et al., 2004. The primary
anti-beclin antibody was obtained from the BD Transduction
Laboratories (Erembodegem, Belgium) and used at 1/250 dilution.
The anti-Akt (dilution 1/1000), Ser 473p-Akt (dilution 1/1000), and
Thr 308p-Akt (dilution 1/500) antibodies were purchased from Cell
Signaling (Beverly, MA). The anti-poly (ADP-ribose) polymerase
antibody (dilution 1/250) came from Calbiochem (VWR, Leuven,
Belgium) and the anti-galectin-1 antibody from Preprotech (Tebu-
Bio). With the exception of the rabbit anti-rat antibody, which was
supplied by Abcam (Cambridge, UK), the secondary antibodies were
acquired from Perbio Science. The integrity and quantity of the
extracts were determined by means of tubulin immunoblotting, with
a rat tubulin antibody used at 1/2000 dilution (Abcam). Blots were
developed using the Pierce supersignal chemiluminescence system
(Perbio Science).
Fluorescence microscopy analyses
The fluorescent detection of protein expression in cells cultured on
glass cover slips was performed as described previously (Lefranc
et al., 2004; Mathieu et al., 2005b; Mijatovic et al., 2006). The
specific binding of the primary antibodies was detected by Alexa
Fluors 488- or Alexa Fluors 594-conjugated secondary antibodies
(dilution 1/400; Molecular Probes Inc., Eugene, OR). The anti-
galectin-1 antibody (dilution 1/200) was provided by Preprotech
(TebuBio) and the anti-Hsp70-antibody (dilution 1/50) by BD
Transduction Laboratories. As an indicator of lysosomal leakage,
cathepsin B immunostaining was carried out using an anti-cathepsin
B antibody (1/50) provided by RD Systems (Abingdon, UK) while the
lysosomes were stained with an anti-lysosomal associated mem-
brane protein 2 antibody (1/50) purchased from ABR Reagents
(BVBA, Zandhoven, Belgium). B16F10 mouse melanoma cells were
fixed, permeabilized, and stained for immunofluorescence analyses
as described previously (Lefranc et al., 2004; Mathieu et al., 2005b;
Mijatovic et al., 2006). The staining patterns of the fluorochromes
were analyzed by means of a computer-assisted fluorescent
Olympus AX70 microscope (Omnilabo, Antwerp, Belgium),
equipped with a Megaview2 digital camera and analySISs software
(Soft Imaging System, Munster, Germany), as detailed previously
(Lefranc et al., 2004; Mathieu et al., 2005b; Mijatovic et al., 2006).
The fluorescent acidophilic Lysotracker dye (Molecular probes
Inc.) was used to stain lysosomes. The protocol was based on
experimental procedures described elsewhere (Kuwada et al., 2005).
Briefly, the cells cultured on coverslips were incubated with 75 nM of
the fluorescent dye at 371C for 1 hour. After washing with
phosphate-buffered saline, they were fixed in 4% formaldehyde for
20 minutes. After mounting on slides, the staining was analyzed by
means of fluorescent microscopy.
Statistical analyses
Survival analyses were carried out by means of Kaplan–Meier curves
and the log-rank test. Statistical comparisons of more than three
independent groups of data were made using the Kruskal–Wallis test
(a nonparametric one-way analysis of variance). In cases where this
test revealed some significant differences or where only two groups
were involved, the Mann–Whitney U-test was applied. All the
statistical analyses were performed using Statistica (Statsoft, Tulsa,
OK).
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